Language:

1-Hexyl n-cyanoacrylate compound (Neucrylate™ AN), a new treatment for berry aneurysm. III: Initial clinical results

Journal of neurointerventional surgery, 2012-01, Vol.4 (1), p.58-61 [Peer Reviewed Journal]

2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;ISSN: 1759-8478 ;EISSN: 1759-8486 ;DOI: 10.1136/jnis.2010.004333 ;PMID: 21990451

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
1-Hexyl n-cyanoacrylate compound (Neucrylate™ AN), a new treatment for berry aneurysm. III: Initial clinical results
Author: Pakbaz, R S ; Shakiba, M ; Ghanaati, H ; Akhlaghpoor, S ; Shakourirad, A ; Kerber, C W
Subjects: Adult ; Aged ; aneurysm ; Aneurysms ; angiography ; Brain ; Cardiovascular disease ; Carotid arteries ; Catheterization - methods ; Cyanoacrylates - administration & dosage ; device ; Dissection ; Female ; Follow-Up Studies ; Hemorrhage ; Humans ; Hypertension ; Intracranial Aneurysm - diagnostic imaging ; Intracranial Aneurysm - surgery ; Male ; Medical imaging ; Middle Aged ; Neck ; Patients ; Pilot Projects ; Radiography ; Studies ; subarachnoid ; Treatment Outcome
Is Part Of: Journal of neurointerventional surgery, 2012-01, Vol.4 (1), p.58-61
Description: IntroductionAs part of an institutionally approved research protocol, patients with cerebral berry aneurysm were enrolled in a clinical trial designed to evaluate the safety of the new moldable liquid embolic agent Neucrylate AN.MethodsTwelve patients with aneurysms judged to be suboptimal for treatment by standard endovascular or surgical approaches were treated with Neucrylate AN. The agent was injected during temporary balloon occlusion at the neck of the aneurysm. The immediate angiographic percentage of aneurysm occlusion and periprocedural adverse events were assessed for each patient. Six-month follow-up angiographic studies were obtained for nine of the 12 patients.ResultsTen of the 12 aneurysms treated (83%) were large to giant (>1.0 cm in diameter), nine (75%) were wide-necked (dome/neck ratio <2.0) and three (25%) were dissecting aneurysms. There were four (33%) periprocedural neurological events. Immediate aneurysm occlusion of >90% was obtained in nine of the 12 cases (75%). There were five recurrences (55.5%) at 6 months.ConclusionThis preliminary clinical series shows that it is feasible to achieve a high percentage of immediate aneurysm occlusion with limited patient morbidity and mortality in the setting of morphologically challenging aneurysms. These preliminary data support larger trials assessing the safety and efficacy of this agent.
Publisher: BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Language: English
Identifier: ISSN: 1759-8478
EISSN: 1759-8486
DOI: 10.1136/jnis.2010.004333
PMID: 21990451
Source: MEDLINE
Alma/SFX Local Collection
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

1-Hexyl n-cyanoacrylate compound (Neucrylate™ AN), a new treatment for berry aneurysm. III: Initial clinical results

Searching Remote Databases, Please Wait